Morningstar

BioMerieux SA BIM

Morningstar Rating
Unlock
Stock XPAR Rating as of
€106.20 −2.00 (1.85%)
View Full Chart
As of Delayed Price Open

Company Report

View Archive

BioMerieux: Narrow Moat Reinstated and Shares Fairly Valued on Refreshed Thoughts

Jay Lee

As we are refreshing our thoughts on BioMerieux, we are reinstating our narrow moat rating. BioMerieux is a niche player in the fragmented in vitro diagnostic market and has specialty positioning in clinical and industrial microbiology and multiplex molecular diagnostics, which is also called syndromic testing. Our fair value estimate is EUR 114 per share, and we view the current market price as fairly valued.

Read Full Report

Price vs Fair Value

View History
BIM is trading at a 368% premium.
Price
€108.20
Fair Value
€593.00
Uncertainty
Medium
1-Star Price
€113.80
5-Star Price
€44.90
Economic Moat
Srnnmy
Capital Allocation
Qbljmssnm

Bulls Say, Bears Say

Bulls

BioMerieux maintains leadership in the niche markets of microbiology testing and multiplex molecular testing, and enjoys growth rates that are well above the IVD industry average.

Bears

BioMerieux is facing more competition in multiplex molecular testing, as other firms are launching newer platforms to compete with BioFire.

Show More

News

View All

Trading Information

Previous Close Price
€108.20
Day Range
€106.20–108.40
52-Week Range
€84.54–111.50
Bid/Ask
€106.10 / €106.30
Market Cap
€12.53 Bil
Volume/Avg
25,167 / 85,255

Key Statistics

Price/Earnings (Normalized)
25.17
Price/Sales
3.38
Dividend Yield (Trailing)
0.79%
Dividend Yield (Forward)
0.79%
Total Yield
0.99%

Company Profile

BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm’s revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l’Etoile, France.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
13,982
Website
http://www.biomerieux.com

Competitors

Valuation

View More
Metric
BIM
DIA
BIO
Price/Earnings (Normalized)
 25.1721.4231.64
Price/Book Value
 3.333.461.43
Price/Sales
 3.385.033.84
Price/Cash Flow
 19.7118.2210.01
Price/Earnings
BIM
DIA
BIO

Financial Strength

Metric
BIM
DIA
BIO
Quick Ratio
 1.201.674.23
Current Ratio
 2.213.126.28
Interest Coverage
 95.7410.35−35.80
Quick Ratio
BIM
DIA
BIO

Profitability

Metric
BIM
DIA
BIO
Return on Assets (Normalized)
 9.17%6.48%2.66%
Return on Equity (Normalized)
 12.83%12.05%3.75%
Return on Invested Capital (Normalized)
 11.23%10.14%2.93%
Return on Assets
BIM
DIA
BIO

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
KhvzsnllpfKtd$234.1 Bil
 Danaher Corp
DHR
BjppghpjdzGhjbb$197.8 Bil
 IQVIA Holdings Inc
IQV
JsmzlmmChfrr$42.2 Bil
 Agilent Technologies Inc
A
LkwmlzghvGkdz$42.1 Bil
 IDEXX Laboratories Inc
IDXX
YfbhnhmdSyzj$40.0 Bil
 Mettler-Toledo International Inc
MTD
TmysrddpwxKpmlcz$31.8 Bil
 Icon PLC
ICLR
McwcjwwrrTfxwjyg$24.4 Bil
 Illumina Inc
ILMN
RwmkprmmwNfglbv$22.1 Bil
 Waters Corp
WAT
QmyhylgltKmmx$21.1 Bil
 Labcorp Holdings Inc
LH
LyyznskwYcnbgc$18.4 Bil

Sponsor Center